Ben Sousa Sells 2,250 Shares of ICU Medical (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) insider Ben Sousa sold 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the sale, the insider directly owned 3,076 shares in the company, valued at $548,512.32. This trade represents a 42.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ICU Medical Stock Performance

Shares of ICUI stock traded down $2.74 during trading hours on Wednesday, reaching $179.34. 314,014 shares of the company’s stock were exchanged, compared to its average volume of 297,162. ICU Medical, Inc. has a fifty-two week low of $110.50 and a fifty-two week high of $192.85. The stock has a market capitalization of $4.48 billion, a P/E ratio of 151.98, a P/E/G ratio of 2.55 and a beta of 0.74. The business has a fifty day moving average price of $153.69 and a 200-day moving average price of $141.31. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter last year, the company posted $2.10 earnings per share. ICU Medical’s quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Analysts predict that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On ICU Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allworth Financial LP bought a new stake in ICU Medical in the second quarter valued at about $26,000. Hilton Head Capital Partners LLC bought a new position in ICU Medical during the fourth quarter worth about $32,000. Covestor Ltd boosted its holdings in ICU Medical by 22.1% during the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 126 shares in the last quarter. Strs Ohio boosted its holdings in ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. Finally, Rockefeller Capital Management L.P. grew its stake in shares of ICU Medical by 21.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 146 shares during the period. 96.10% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ICUI. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. KeyCorp boosted their price target on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Finally, Needham & Company LLC raised their price objective on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $192.80.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.